methyl (6-(4-acetoamidophenoxy)azaindolizine-2-yl)carbamate | 433226-18-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl (6-(4-acetoamidophenoxy)azaindolizine-2-yl)carbamate
• 英文别名: methyl N-[6-(4-acetamidophenoxy)imidazo[1,2-a]pyridin-2-yl]carbamate
• CAS: 433226-18-7
• 化学式: C₁₇H₁₆N₄O₄
• 分子量: 340.338
• InChiKey: ZJYIMLHKZKIPPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  94
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl (6-(4-acetoamidophenoxy)azaindolizine-2-yl)carbamate 在 盐酸 作用下， 反应 1.0h， 生成 methyl (6-(4-aminophenoxy)azaindolizine-2-yl)carbamate
  参考文献：
  名称：

  Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and VEGFR-2 Tyrosine Kinase Receptors

  摘要：

  We herein disclose a novel chemical series of benzimidazole-ureas as inhibitors of VEGFR-2 and TIE-2 kinase receptors, both of which are implicated in angiogenesis. Structure-activity relationship (SAR) studies elucidated a critical role for the NI nitrogen of both the benzimidazole (segment E) and urea (segment B) moieties. The SAR results were also supported by the X-ray crystallographic elucidation of the role of the NI nitrogen and the urea moiety when the benzimidazole-urea compounds were bound to the VEGFR-2 enzyme. The left side phenyl ring (segment A) occupies the backpocket where a 3-hydrophobic substituent was favored for TIE-2 activity.

  DOI：

  10.1021/jm0611051
• 作为产物：
  描述：

  对乙酰氨基酚 在 palladium on activated charcoal 氢气 、 caesium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 methyl (6-(4-acetoamidophenoxy)azaindolizine-2-yl)carbamate
  参考文献：
  名称：

  Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and VEGFR-2 Tyrosine Kinase Receptors

  摘要：

  We herein disclose a novel chemical series of benzimidazole-ureas as inhibitors of VEGFR-2 and TIE-2 kinase receptors, both of which are implicated in angiogenesis. Structure-activity relationship (SAR) studies elucidated a critical role for the NI nitrogen of both the benzimidazole (segment E) and urea (segment B) moieties. The SAR results were also supported by the X-ray crystallographic elucidation of the role of the NI nitrogen and the urea moiety when the benzimidazole-urea compounds were bound to the VEGFR-2 enzyme. The left side phenyl ring (segment A) occupies the backpocket where a 3-hydrophobic substituent was favored for TIE-2 activity.

  DOI：

  10.1021/jm0611051

文献信息

• CHEMICAL COMPOUNDS
  申请人：Cheung Mui

  公开号：US20070249600A1

  公开（公告）日：2007-10-25

  Benzimidazole derivatives, which are useful as TIE-2 and/or VEGFR2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

  本文描述了作为TIE-2和/或VEGFR2抑制剂有用的苯并咪唑衍生物。所述发明还包括制备这种苯并咪唑衍生物的方法，以及在治疗过度增生性疾病中使用它们的方法。
• HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：Hirose Masaaki

  公开号：US20100249119A1

  公开（公告）日：2010-09-30

  The present invention provides a heterocyclic compound having a strong Raf inhibitory activity, which is represented by the following formula wherein each substituent is as defined in the present specification, or a salt thereof.

  本发明提供了一种具有强烈的Raf抑制活性的杂环化合物，其由以下公式表示，其中每个取代基如本规范中所定义的，或其盐。
• FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF
  申请人：OGURO Yuya

  公开号：US20090163488A1

  公开（公告）日：2009-06-25

  A compound represented by the formula (I): wherein Z 1 , Z 2 , Z 3 and Z 4 are the following combination, (Z 1 ,Z 2 ,Z 3 ,Z 4 )=(CR 4 ,N,CR 5 ,C), (N,N,CR 5 ,C), (N,C,CR 5 ,N), (S,C,CR 5 ,C) or (S,C,N,C); R 1 and R 2 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group bonded via a carbon atom, (4) a group bonded via a nitrogen atom, (5) a group bonded via an oxygen atom or (6) a group bonded via a sulfur atom; R 3 is an amino optionally having substituent(s); R 4 and R 5 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group bonded via a carbon atom, (4) a group bonded via a nitrogen atom, (5) a group bonded via an oxygen atom or (6) a group bonded via a sulfur atom; R 3 and R 4 optionally form a ring optionally having substituent(s); and a group represented by the formula is a cyclic group optionally having substituent(s), or a salt thereof.

  化合物的分子式为（I）：其中Z1，Z2，Z3和Z4是以下组合，（Z1，Z2，Z3，Z4）=（CR4，N，CR5，C），（N，N，CR5，C），（N，C，CR5，N），（S，C，CR5，C）或（S，C，N，C）; R1和R2相同或不同，每个都是（1）氢原子，（2）卤原子，（3）通过碳原子键合的基团，（4）通过氮原子键合的基团，（5）通过氧原子键合的基团或（6）通过硫原子键合的基团; R3是氨基，可以有取代基; R4和R5相同或不同，每个都是（1）氢原子，（2）卤原子，（3）通过碳原子键合的基团，（4）通过氮原子键合的基团，（5）通过氧原子键合的基团或（6）通过硫原子键合的基团; R3和R4可以选择形成一个环，也可以有取代基; 以及由公式表示的基团是一个环状基团，可以有取代基，或其盐。
• HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2162445A1

  公开（公告）日：2010-03-17
• US8304557B2
  申请人：——

  公开号：US8304557B2

  公开（公告）日：2012-11-06